Sugi Predict

Sugi Predict / Compounds / SCHEMBL4106504

SCHEMBL4106504

SCHEMBL4106504

NS(=O)(=O)c1csc(Cl)c1

nearest known ligand 0.47

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ CA2 P00918 15/20 0.45
▸ CA1 P00915 12/20 0.45
▸ CA9 Q16790 11/20 0.45
▸ CA12 O43570 5/20 0.43
▸ CA4 P22748 5/20 0.43
▸ CA14 Q9ULX7 5/20 0.43
▸ CA6 P23280 4/20 0.43
▸ CA5A P35218 4/20 0.43
▸ CA7 P43166 4/20 0.43
▸ CA5B Q9Y2D0 4/20 0.43
▸ CA13 Q8N1Q1 3/20 0.43
▸ CA3 P07451 3/20 0.43
▸ PLA2G7 Q13093 1/20 0.41
▸ LMNA P02545 1/20 0.41
▸ CYP2C9 P11712 1/20 0.41
▸ POLB P06746 1/20 0.41
▸ APEX1 P27695 1/20 0.41
▸ TDP1 Q9NUW8 1/20 0.41
▸ L3MBTL1 Q9Y468 1/20 0.41
▸ DAO P14920 1/20 0.39

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9140997 0.81 DAO (0.41) CA2LMNADAO
Hydrochloric Acid SCHEMBL31601091 0.81 DAO (0.35) CA2CA1CA9CA12CA4
SCHEMBL4875871 0.79 ALDH1A1 (0.42) TDP1DAO
SCHEMBL5355039 0.77 DAO (0.43) CA2LMNATDP1DAO
Hydrochloric Acid SCHEMBL27687522 0.76 DAO (0.42) CA2LMNATDP1DAO
SCHEMBL28047295 0.74 CA2 (0.59) CA2
SCHEMBL27174852 0.74 CA2 (0.46) CA2CA1CA9CA12CA4
SCHEMBL25208792 0.73 CA2 (0.46) CA2CA1CA9CA12CA4
SCHEMBL23568848 0.73 CA2 (0.45) CA2CA1CA9CA12CA4
SCHEMBL23531916 0.73 CA2 (0.41) CA2CA1CA9CA12CA4

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 21 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-4573088-A1 HETEROCYCLE RBM39 MODULATORS Recursion Pharmaceuticals, Inc. (US) 2025-06-25 — — EP disclosed
WO-2025108986-A1 2-AMINO-N-(OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2025-05-30 — — WO disclosed
CN-119630658-A Heterocyclic RBM39 modulators 递归医药公司 2025-03-14 — — CN disclosed
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use Oxford Drug Design Limited (GB) 2025-03-11 — — US disclosed
CN-114846000-B 2-Amino-N- (amino-oxo-aryl-lambda 6-sulfinyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2025-01-03 — — CN disclosed
US-20240092770-A1 Heterocycle RMB39 Modulators RECURSION PHARMACEUTICALS, INC. 2024-03-21 — — US disclosed
WO-2024039689-A1 HETEROCYCLE RBM39 MODULATORS RECURSION PHARMACEUTICALS, INC. (US) 2024-02-22 — — WO disclosed
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2023-04-13 — — US disclosed
EP-4077289-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2022-10-26 — — EP disclosed
CN-114846000-A 2-amino-N- (amino-oxo-aryl- λ 6-thioalkyl) acetamide compounds and therapeutic uses thereof 牛津药物设计有限公司 2022-08-02 — — CN disclosed
WO-2021123237-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE Oxford Drug Design Limited (GB) 2021-06-24 — — WO disclosed
US-20090227555-A2 Novel Pyridine Compounds ASTRAZENECA AB (SE) 2009-09-10 — — US disclosed
US-20090042852-A1 Novel Pyridine Compounds ASTRAZENECA AB (SE) 2009-02-12 — — US disclosed
US-20080312208-A1 Pyridine Analogues ASTRAZENECA AB (SE) 2008-12-18 — — US disclosed
EP-1904474-A1 NEW PYRIDINE ANALOGUES AstraZeneca AB (SE) 2008-04-02 — — EP disclosed
CN-101137643-A Novel pyridine compounds ASTRAZENECA AB (SE) 2008-03-05 — — CN disclosed
EP-1836189-A1 NOVEL PYRIDINE COMPOUNDS AstraZeneca AB (SE) 2007-09-26 — — EP disclosed
WO-2006073361-A9 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2007-08-02 — — WO disclosed
WO-2007008140-A1 NEW PYRIDINE ANALOGUES ASTRAZENECA AB (SE) 2007-01-18 — — WO disclosed
WO-2006073361-A1 NOVEL PYRIDINE COMPOUNDS ASTRAZENECA AB (SE) 2006-07-13 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12247004-B2 2-amino-N-(amino-oxo-aryl-lambda6-sulfanylidene)acetamide compounds and their therapeutic use AARS1, ASNS, GARS1 CA2 2761/4885CA1 4200/4885CA9 4146/4885
US-20090042852-A1 Novel Pyridine Compounds P2RY12, P2RY11, P2RY1 CA2 2671/4885CA1 4752/4885CA9 3973/4885
US-20090227555-A2 Novel Pyridine Compounds P2RY12, P2RY1, P2RY11 CA2 3705/4885CA1 4864/4885CA9 4594/4885
US-20080312208-A1 Pyridine Analogues P2RY12, P2RY11, P2RY1 CA2 3694/4885CA1 4880/4885CA9 4611/4885
US-20230114875-A1 2-AMINO-N-(AMINO-OXO-ARYL-LAMBDA6-SULFANYLIDENE)ACETAMIDE COMPOUNDS AND THEIR THERAPEUTIC USE AARS1, ASNS, GARS1 CA2 2761/4885CA1 4200/4885CA9 4146/4885
US-20240092770-A1 Heterocycle RMB39 Modulators PRMT9, RCC2, RBBP9 CA2 4825/4885CA1 4867/4885CA9 3056/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.